Ocular Therapeutix reports Q2 EPS (64c), consensus (56c)
Reports Q2 revenue $438,000, consensus $490,000. "This is an important time for Ocular Therapeutix as we focus our efforts on the resubmission of our NDA for DEXTENZA for the treatment of post-surgical ocular pain while continuing to advance our pipeline programs," said Antony Mattessich, Chief Executive Officer. "My goal as CEO is to fully realize the opportunities for Ocular Therapeutix by deepening the Company's expertise in biopharmaceuticals. I believe our hydrogel technology represents an important innovation in the field of ophthalmology and has great potential to improve outcomes across a wide range of diseases of the eye by improving the performance of both small and large molecules. We are focused on execution and working as diligently as possible to achieve our vision."